| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
5,923 |
5,103 |
$1.36M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,940 |
1,597 |
$969K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,438 |
3,861 |
$635K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,906 |
4,276 |
$571K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,475 |
2,119 |
$551K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,200 |
1,410 |
$529K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,485 |
3,083 |
$460K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,510 |
1,310 |
$310K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,684 |
2,047 |
$287K |
| 70450 |
Computed tomography, head or brain; without contrast material |
893 |
571 |
$194K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
653 |
570 |
$138K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,623 |
1,405 |
$116K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,824 |
2,457 |
$92K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,208 |
1,459 |
$90K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
285 |
178 |
$62K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,305 |
1,147 |
$62K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,623 |
1,467 |
$57K |
| 80053 |
Comprehensive metabolic panel |
6,870 |
5,395 |
$46K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
244 |
191 |
$43K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
734 |
631 |
$39K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
239 |
194 |
$32K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,230 |
5,570 |
$30K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
74 |
67 |
$21K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,050 |
415 |
$19K |
| 84484 |
|
3,078 |
1,836 |
$14K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
56 |
54 |
$14K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
165 |
152 |
$12K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,105 |
1,720 |
$12K |
| 71045 |
Radiologic examination, chest; single view |
3,258 |
1,877 |
$12K |
| 71046 |
Radiologic examination, chest; 2 views |
988 |
707 |
$11K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,950 |
2,250 |
$10K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
208 |
64 |
$10K |
| 81001 |
|
3,031 |
2,550 |
$9K |
| 83690 |
|
1,934 |
1,573 |
$8K |
| 87631 |
|
98 |
92 |
$7K |
| 85379 |
|
1,237 |
1,089 |
$6K |
| 82150 |
|
1,661 |
1,376 |
$6K |
| 83735 |
|
2,017 |
1,642 |
$6K |
| 86140 |
|
2,012 |
1,700 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,233 |
1,031 |
$5K |
| 81025 |
|
746 |
626 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,049 |
908 |
$4K |
| 83605 |
|
1,155 |
916 |
$4K |
| 84145 |
|
519 |
427 |
$4K |
| 83880 |
|
424 |
351 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
450 |
388 |
$4K |
| 99350 |
Prolong home eval add 15m |
142 |
115 |
$4K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,082 |
1,667 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
8,038 |
5,922 |
$3K |
| 82962 |
|
1,750 |
968 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
40 |
38 |
$2K |
| 81003 |
|
1,308 |
1,108 |
$2K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
17 |
13 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
143 |
125 |
$2K |
| 85610 |
|
1,358 |
1,075 |
$2K |
| G0382 |
Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
44 |
41 |
$2K |
| 82550 |
|
671 |
562 |
$2K |
| 87040 |
|
624 |
294 |
$1K |
| 87077 |
|
329 |
250 |
$1K |
| 80306 |
|
109 |
98 |
$1K |
| 87634 |
|
20 |
17 |
$1K |
| 85730 |
|
520 |
441 |
$1K |
| 85652 |
|
700 |
623 |
$1K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
57 |
52 |
$1K |
| 87186 |
|
247 |
197 |
$980.41 |
| 74022 |
|
222 |
145 |
$933.08 |
| 87081 |
|
110 |
99 |
$849.21 |
| 82077 |
|
88 |
65 |
$818.88 |
| 80050 |
General health panel |
95 |
80 |
$695.44 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
198 |
126 |
$599.95 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
19 |
12 |
$594.00 |
| 85027 |
|
147 |
114 |
$487.44 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
16 |
15 |
$400.91 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,881 |
1,395 |
$317.18 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
26 |
14 |
$297.76 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
19 |
19 |
$267.31 |
| 97162 |
|
13 |
12 |
$250.64 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
13 |
13 |
$250.00 |
| 73630 |
|
17 |
13 |
$231.32 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,555 |
1,302 |
$214.78 |
| 73030 |
|
17 |
12 |
$181.40 |
| 96127 |
|
18 |
14 |
$176.40 |
| 73562 |
|
14 |
12 |
$131.38 |
| 96376 |
|
49 |
41 |
$102.10 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,191 |
1,564 |
$101.46 |
| 80061 |
Lipid panel |
13 |
12 |
$82.14 |
| 94664 |
|
71 |
64 |
$66.09 |
| J3490 |
Unclassified drugs |
283 |
211 |
$64.73 |
| J7050 |
Infusion, normal saline solution, 250 cc |
2,031 |
864 |
$54.57 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
15 |
14 |
$52.65 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,765 |
1,353 |
$37.98 |
| 85007 |
|
15 |
12 |
$23.74 |
| G0378 |
Hospital observation service, per hour |
34 |
26 |
$8.54 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
739 |
545 |
$7.44 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
234 |
183 |
$5.79 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
91 |
63 |
$3.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
326 |
192 |
$3.12 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
123 |
99 |
$2.14 |
| J2704 |
Injection, propofol, 10 mg |
319 |
92 |
$1.18 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
229 |
160 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
134 |
109 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
15 |
13 |
$0.00 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
47 |
38 |
$0.00 |
| A4606 |
Oxygen probe for use with oximeter device, replacement |
88 |
75 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
13 |
12 |
$0.00 |